PHOSPHOTEC
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOSPHOTEC is an injectable diagnostic or radiopharmaceutical product developed by Bracco, approved in 1976. The specific mechanism of action and clinical indications are not disclosed in available data. This product represents a legacy asset in Bracco's portfolio with established market presence.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting potential headcount rationalization or transition planning within the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PHOSPHOTEC is a legacy product with minimal current career development signals (0 linked jobs), positioning it as a maintenance-mode asset rather than a growth opportunity. Career advancement on this product is limited; professionals should consider it a stepping stone toward higher-priority portfolio brands or evaluate lateral moves within Bracco.
Brand ManagerRegional Sales Manager
Worked on PHOSPHOTEC at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.